Last Update 23 Apr 26

TNG: Phase II Head And Neck Progress Will Drive Future Repricing

Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view.

Analyst Commentary

Bullish Takeaways

Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.
The updated P/E assumptions are seen as aligning the model more closely with peers, which, in their view, reduces the risk of the stock looking mispriced on standard earnings multiples.
Refinements to margin expectations are interpreted as a sign that analysts have better clarity on the path from pipeline investment to potential profitability, even if that path remains model based.
Some bullish analysts suggest that maintaining the target price through this update reflects confidence that execution can match the refreshed financial assumptions over time.

Bearish Takeaways

Bearish analysts focus on the need to revise discount rates and profit margins at all, seeing it as a reminder that the valuation is still sensitive to changes in modeling inputs and not yet anchored by large, recurring earnings.
They also flag that the reliance on future P/E assumptions keeps a meaningful portion of the valuation tied to anticipated outcomes rather than current cash flows.
Some bearish analysts interpret the broadly steady €1.10 target as a sign that upside is limited in the near term without clearer evidence of execution progress versus the updated assumptions.
There is also caution that any further tweaks to risk parameters or profitability timelines could affect the target, which may keep more conservative investors on the sidelines.

What's in the News

Transgene completed patient randomization for the Phase 2 part of its Phase 1/2 trial of TG4050 in adjuvant treatment of HPV negative head and neck cancer, with 38 patients now randomized in the study. (Key Developments)
The primary endpoint of the TG4050 trial is 2 year disease free survival, with top line results expected by the end of first quarter 2028 once all Phase 2 patients reach 2 year follow up or experience an event such as relapse or death. (Key Developments)
Phase 1 data for TG4050 in HPV negative head and neck cancer showed that multiple subcutaneous injections were well tolerated with no unexpected safety signals, and that all patients treated with TG4050 were disease free at 2 years with a median follow up of 30 months. (Key Developments)
Transgene expects 3 year disease free survival follow up data from the Phase 1 part of the TG4050 trial in the second or third quarter of 2026, which may give investors additional insight into longer term outcomes for this individualized vaccine approach. (Key Developments)
A comprehensive analysis of clinical and translational data from the Phase 1 part of the TG4050 trial was published on medRxiv in January 2026 and is under review by a peer reviewed journal, adding more detail on how this individualized neoantigen vaccine is performing in early stage testing. (Key Developments)

Valuation Changes

Fair Value: The €1.10 fair value estimate is unchanged, suggesting the overall valuation framework has been retained.
Discount Rate: The discount rate has risen slightly from 6.42% to about 6.50%, implying a modestly higher required return in the model.
Revenue Growth: Revenue growth assumptions are essentially flat at about 99.44%, indicating no material change to topline expectations in the model.
Net Profit Margin: The projected profit margin has risen slightly from 35.40% to about 35.86%, reflecting a small adjustment to long term profitability assumptions.
Future P/E: The future P/E multiple has risen significantly from about 12.5x to about 21.7x, which increases the weight of earnings expectations in the overall valuation.

2 views

Key Takeaways

Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.
Enhanced manufacturing capabilities are expected to improve net margins by reducing costs and increasing efficiency.
Uncertainty from missed trial objectives and strategic delays, alongside reliance on external funding, could challenge Transgene's revenue growth and financial stability.

Catalysts

About Transgene

A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.What are the underlying business or industry changes driving this perspective?

The progression to a Phase II trial for TG4050, an individualized therapeutic cancer vaccine, could boost future revenue by establishing Transgene as a key player in the neoantigen therapeutic cancer vaccine market.
The expected presentation of 24-month follow-up data and long-term immunogenicity data for TG4050 in 2025 might enhance Transgene's reputation and validation, potentially increasing revenue as the data could support further development and partnerships.
Initiating a new Phase I trial for TG4050 in a second indication expected in Q4 2025 presents a growth opportunity in expanding the use of their myvac platform, potentially impacting revenue streams positively by entering additional markets.
Significant advancements in manufacturing capabilities, aiming for a rapid, integrated, and scalable process, are likely to improve net margins by reducing production costs and increasing efficiency as the program advances.
Additional data releases from other pipeline assets like TG4001 and BT-001 scheduled for 2025 could drive revenue growth by demonstrating positive outcomes in treating specific cancer types and supporting potential new treatment indications.

Transgene Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Transgene's revenue will grow by 99.4% annually over the next 3 years.
Analysts are not forecasting that Transgene will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Transgene's profit margin will increase from -520.4% to the average GB Biotechs industry of 35.9% in 3 years.
If Transgene's profit margin were to converge on the industry average, you could expect earnings to reach €20.5 million (and earnings per share of €0.06) by about April 2029, up from -€37.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 21.7x on those 2029 earnings, up from -5.5x today. This future PE is greater than the current PE for the GB Biotechs industry at 16.6x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.5%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The TG4001 trial did not meet its primary objective for progression-free survival in the overall patient population, which could dampen investor confidence and negatively impact future revenue expectations.
The challenges associated with intravenous administration of TG6050, including potential neutralization by the patient’s immune system, may limit its efficacy and could result in higher-than-anticipated development costs, impacting net margins.
The final strategy for BT-001 has not yet been defined, introducing uncertainty about the asset's future prospects and its potential impact on Transgene's revenue growth.
Delays or extensions in trial timelines, such as the 2027 completion date for TG4050 Phase II efficacy analysis, may lead to increased operational costs and delay revenue recognition, affecting earnings.
Dependence on partnerships and external funding, as evidenced by the credit facility from TSGH, may indicate potential cash flow issues that could affect the company’s financial stability beyond April 2026.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €1.1 for Transgene based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €57.2 million, earnings will come to €20.5 million, and it would be trading on a PE ratio of 21.7x, assuming you use a discount rate of 6.5%.
Given the current share price of €0.75, the analyst price target of €1.1 is 31.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Transgene?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines